NJ-ZYCUS
4.4.2024 17:01:26 CEST | Business Wire | Press release
Zycus, a global leader in cognitive procurement technology solutions, set another new milestone by announcing integration with Microsoft Azure OpenAI Service. This integration is a step towards an ongoing effort to build the world’s first generative AI powered S2P platform. This continuous engagement will harness the power of advanced AI to transform end to end source to pay processes, offering unprecedented efficiency, compliance, and ease of use.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240401357521/en/
Zycus launched world's first Generative AI powered S2P platform in collaboration with Microsoft (Graphic: Business Wire)
Zycus has already incorporated various Generative AI capabilities in the existing S2P Suite under the Merlin Assist offering. It is available both through an App published on Microsoft Teams and via Zycus web app.
“We are thrilled to partner with Microsoft. Many of our clients, global enterprises from across the world, have deployed Merlin Assist as part of our early access program and share very encouraging feedback on ease of use, compliance, and productivity. We are certain that sourcing & procurement will be fundamentally transformed in the months to come,” said Aatish Dedhia, Founder & CEO of Zycus.
Samik Roy, Executive Director, Corporate Medium and Small Businesses, Microsoft India said, “AI will transform the way individuals, teams and organizations work. Zycus has integrated Azure OpenAI to infuse AI into its S2P Platform. The quantitative impact is very encouraging. From personalized experiences to streamlined workflows, AI will start becoming the cornerstone of Zycus’ customers’ success.”
Some top use cases of Generative AI are enhancing the complete S2P process:
1. Efficiency and Time-Saving Innovations:
Harnessing the power of Azure OpenAI Service, Zycus can enhance the end-to-end procurement lifecycle, starting from swift recommendations of alternate suppliers to simplifying contract management with abstract language contract processing. Zycus has also built autoscore RFP capability that accelerates proposal evaluations. These innovations reduce manual efforts, saving valuable time and minimizing errors.
2. Enhanced Source Aggregation and Risk Assessment:
Zycus users are empowered with powerful source aggregation and tracking, combined with robust risk assessment. Azure OpenAI Service’s advanced algorithms process thousands of articles daily delivering a fourfold boost in article processing throughput. iRisk generates compliance-related questionnaires, easing the assessment process while offering strategic suggestions for mitigating identified risks. This approach streamlines compliance processes and delivers actionable strategies for enhanced predictive risk management.
3. Democratized Procurement via Microsoft Teams:
Zycus has seamlessly integrated its platform with Microsoft Teams to boost adoption. This integration makes procurement accessible to everyone. From policy adherence, extracting contract line items to comprehensive supplier response summaries and RFQ (Request For Quotation) questionnaire generation, all the features are built to continuously enhance user experience and get maximum ROI from the platform.
4. Precision-Driven AI Models for Informed Decisions:
The integration ensures more accurate, data-driven insights on alternative items, PR/PO summaries, and price trends, facilitating smarter purchasing choices procurement decisions, minimizing risks and optimizing outcomes.
“By combining the strengths of Azure OpenAI with Zycus’ native source to pay platform, we are setting a new standard in the industry. Our clients can now experience enhanced efficiency, risk management, and user engagement, driving procurement transformation at scale,” said Aatish Dedhia.
About Zycus
Zycus is a leading global provider of end-to-end Source to Pay solutions, pioneering in the space of cognitive procurement, powered by its advanced Merlin AI Suite. With a strong emphasis on transforming the procurement landscape, Zycus leverages Generative AI to offer innovative, AI-driven capabilities that streamline procurement processes, enhance decision-making, and foster strategic sourcing and supplier management.
To see the Microsoft and Zycus integrated platform in action, join us on April 9, 1 PM - 2:30 PM ET.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240401357521/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom